The race is on. Competitive advantage rests with those who find ways to quickly and effectively identify promising new therapeutic treatments and diagnostic tools from enormous and complex data sets.

In recent years, scores of software vendors have produced tools for the analysis of gene expression array data, but none has exponentially improved the process of identifying promising genomic biomarkers. In addition, none has produced tools that generate results consistent with the statistical principles adopted by regulating agencies.

Using patent pending technologies developed at Fred Hutchinson Cancer Research Center in Seattle, Enodar has developed unique approaches to addressing the negative impact of technical and sample variations on scientific conclusions. The result is higher quality biomarker identification, reduced false positives, and a significant improvement in the value of array expression. We call this approach True Discovery™.